Shopping Cart
- Remove All
- Your shopping cart is currently empty
Targapremir-210 (TGP-210) is a selective and potent inhibitor of miRNA-210 (miRNA-210), which inhibits pre-miR-210 processing and induces apoptosis in breast cancer cells.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $232 | In Stock |
Description | Targapremir-210 (TGP-210) is a selective and potent inhibitor of miRNA-210 (miRNA-210), which inhibits pre-miR-210 processing and induces apoptosis in breast cancer cells. |
Targets&IC50 | miR-210:200 nM |
In vitro | Targapremir-210 selectively reduces mature miR-210 levels in MDA-MB-231 cells under hypoxic conditions, achieving an IC50 of approximately 200 nM[1]. This compound specifically induces apoptosis in MDA-MB-231 cells exposed to hypoxia at 200 nM, while it does not trigger apoptosis in cells cultivated in normoxic environments[1]. |
In vivo | In vivo, a single intraperitoneal injection of Targapremir-210 (100 μL of 200 nM) impedes the proliferation of MDA-MB-231 triple-negative breast cancer (TNBC) cells. Targapremir-210 successfully reaches the tumor and sustains its presence throughout the entire 21-day period, leading to a reduction in tumor burden in a TNBC mouse model[1]. |
Alias | TGP-210 |
Molecular Weight | 592.69 |
Formula | C32H36N10O2 |
Cas No. | 1049722-30-6 |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 100 mg/mL (168.72 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.